Drug Shortage Report for MANNITOL INJECTION, USP
Report ID | 162159 |
Drug Identification Number | 02243176 |
Brand name | MANNITOL INJECTION, USP |
Common or Proper name | MANNITOL INJECTION, USP |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | MANNITOL |
Strength(s) | 25% |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 50mL |
ATC code | B05BC |
ATC description | I.V. SOLUTIONS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2022-06-02 |
Estimated end date | 2022-10-12 |
Actual end date | 2022-10-12 |
Shortage status | Resolved |
Updated date | 2022-10-13 |
Company comments | On 100% allocation until September 30, 2022. We will be encountering a supply interruption on our Mannitol Injection 250 mg/mL SD Vial 50 mL effective October 1, 2022 until October 12, 2022. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v7 | 2022-10-13 | English | Compare |
v6 | 2022-10-02 | French | Compare |
v5 | 2022-10-02 | English | Compare |
v4 | 2022-09-01 | French | Compare |
v3 | 2022-09-01 | English | Compare |
v2 | 2022-06-08 | French | Compare |
v1 | 2022-06-08 | English | Compare |
Showing 1 to 7 of 7